TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
4.970
+0.420 (9.23%)
At close: Jun 26, 2026, 4:00 PM EDT
4.830
-0.140 (-2.82%)
After-hours: Jun 26, 2026, 6:14 PM EDT
TransCode Therapeutics Employees
TransCode Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 5 or 71.43% compared to the previous year.
Employees
12
Change (1Y)
5
Growth (1Y)
71.43%
Revenue / Employee
n/a
Profits / Employee
-$3,641,348
Market Cap
4.72M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| CollPlant Biotechnologies | 39 |
| GeoVax Labs | 19 |
| FibroBiologics | 15 |
| Ensysce Biosciences | 10 |
| Dermata Therapeutics | 9 |
| Artelo Biosciences | 7 |
| Enveric Biosciences | 6 |
RNAZ News
- 9 days ago - TransCode Therapeutics Slides: Investor presentation - Filings
- 19 days ago - TransCode Therapeutics to Host R&D Webcast on June 18, 2026 - PRNewsWire
- 24 days ago - Transcode reports results from Phase 1a dose escalation trial with TTX-MC138 - TheFly
- 24 days ago - TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PRNewsWire
- 25 days ago - TransCode Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Transcode Therapeutics initiates Phase 2a clinical trial with TTX-MC138 - TheFly
- 4 weeks ago - TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer - PRNewsWire
- 4 weeks ago - TransCode Therapeutics Proxy statement: Proxy filing - Filings